FDA-approved
Digestive & weight
Terlipressin
Evidence
FDA approved
Class
Vasopressin analog
KEY TAKEAWAY
Terlipressin is a synthetic analog of vasopressin that the body converts to its active form. It is sold as Terlivaz. The FDA approved terlipressin (Terlivaz) in 2022 to improve kidney function in adults with hepatorenal syndrome.
Written by the Veylo editorial team · Updated
November 2026
What it is
Vasopressin analog
Approved for
Hepatorenal syndrome with rapidly declining kidney function
Key fact
The FDA approved terlipressin (Terlivaz) in 2022 to improve kidney function in adults with hepatorenal syndrome.
Route
Intravenous injection
Evidence strength
FDA approved
Terlipressin is a synthetic analog of vasopressin that the body converts to its active form. It is sold as Terlivaz.
It narrows blood vessels in the gut, which redirects blood flow toward the kidneys in people with advanced liver disease.
The FDA approved terlipressin (Terlivaz) in 2022 to improve kidney function in adults with hepatorenal syndrome.
Hepatorenal syndrome with rapidly declining kidney function.
The label carries a boxed warning for serious or fatal respiratory failure, so people with low oxygen or fluid overload are at higher risk.
U.S. FDA prescribing information for Terlipressin. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.